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Abstract Lung cancer is the most common cancer world-
wide as well as the leading cause of cancer related deaths as
reported by Torre et al (CA Cancer J Clin 65:87–108, 2015].
Non-small cell lung cancer (NSCLC) accounts for up to 85 %
of all lung cancers. Multiple advances in the staging, diag-
nostic procedures, therapeutic options, as well as molecular
knowledge have been achieved during the past years, although
the overall outlook has not greatly changed for the majority of
patients with the overall 5-year survival having marginally
increased over the last decade from 15.7 to 17.4 % as reported
by Howlader et al. (SEER Cancer Statistics Review 2015).
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Methodology
Relevant studies published in peer review journals were
used for the guideline elaboration. The Infectious Dis-
eases Society of America grading system was used to
assign levels of evidence and grades of
recommendation.
Diagnosis
Anatomopathological diagnosis of non-small cell lung
cancer should be made according to the World Heath
Organization (WHO) classification. The International
Association for the Study of Lung Cancer (IASLC) pro-
vided adenocarcinoma classification as well as key rec-
ommendations for the management of small biopsies and
cytology [3]. For therapeutic implications, specific sub-
typing of NSCLC is strongly recommended whenever
possible. A limited diagnostic workup is also recom-
mended to preserve as much tissue as possible for further
molecular assessments. Evidence-based recommendations
for molecular testing in lung cancer have been recently
updated by SEOM–SEAP (Spanish Society of Medical
Oncology–Spanish Society of Pathology) [4] (Table 3).
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Staging
In NSCLC the following staging work-up is highly
recommended:
• Clinical history, including smoking and family history;
physical examination, performance status (PS) and
weight loss should be assessed.
• Blood test, including hematology, renal and hepatic
function.
• Chest and upper abdomen (including liver and adrenal
glands) computerized tomography (CT).
• Brain CT or magnetic resonance imaging (MRI) if there
are neurological symptoms in the physical examination.
• Bone scan if there is bone pain, high serum calcium or
high alkaline phosphatase.
In patients undergoing potentially radical treatment, the
following recommendations should be considered:
• Whole-body FDG-positron emission tomography
(PET)-CT
• Bronchoscopy
• Pulmonary function tests
• Ergospirometry if the pulmonary function tests are not
normal
• Chest MRI in Pancoast tumour
• Invasive mediastinal staging, endobronchial ultra-
sound-guided fine-needle aspiration (EBUS-FNA),
and/or endoscopic ultrasound guided fine-needle aspi-
ration (EUS-FNA), is recommended in patients with
PET positive mediastinal or hilar lymph nodes (LNs).
For patients with suspect LNs on imaging and negative
EBUS/EUS results, an additional mediastinoscopy is
recommended. In patients with PET-negative LNs,
invasive staging is also recommended in CT enlarged
mediastinal LNs ([1.5 cm) and in patients with central
tumours.
• Histological and cytological confirmation is strongly
recommended in the presence of pleural/pericardial
effusion or isolated metastatic site.
Staging system
NSCLC is staged according to the UICC system (7th edi-
tion), grouped into stage categories (Tables 1 and 2) [5].




Patients with clinically stage I–II NSCLC should be eval-
uated in a multidisciplinary tumor board and a preoperative
pulmonary assessment is recommended to identify patients
at increased risk of post-operative complications following
lung cancer.
Surgery
Surgical resection is the treatment of choice for patients
with early-stage NSCLC, and yields the best potential cure
rate in patients with stage I–II and no medical contraindi-
cations to operative intervention (IB).
The surgical resection used will depend on the extent of
the disease, the location of the tumor and the cardiopul-
monary reserve of the patient:
• In stage I–II NSCLC patients who are medically fit for
surgery, a lobectomy or anatomic pulmonary resection
is recommended rather than a sublobar resection (IB)
[6]. Systematic mediastinal lymph node sampling or
dissection at the time of anatomic resection is also
recommended for accurate staging over selective or no
sampling [7] (IB).
• A sublobar resection (segmentectomy or a non-anatom-
ical wedge resection) is recommended for those
patients who cannot tolerate a lobectomy due to
comorbidities or decreased pulmonary function (IB).
• A sublobar resection with negative margins can be
considered for patients with small peripheral nodules
(B1 cm) with a predominantly ground glass opacity (IB).
• In central tumors, a sleeve lobectomy is the preferred
type of resection over a pneumonectomy (IIC).
• Re-resection is recommended for patients with positive
margins in resected stage I-II NSCLC. If re-resection is
Table 1 Staging Grouping (Adapted from Goldstraw et al. [5])
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a, b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a,b N1 M0
T2a N1
T2b N0
Stage IIB T2b N1
T3 N0
Stage IIIA T1,T2 N2
T3 N1,N2
T4 N0,N1
Stage IIIb T4 N2
Any T N3
Stage IV Any T Any N M1a,b
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not possible, postoperative radiotherapy (PORT) should
be considered [8].
Adjuvant therapy
The beneficial effect in terms of survival of adjuvant cis-
platin based chemotherapy in completely resected fit stage
II–III NSCLC patients is now well established [9].
• For patients with completely resected stage II NSCLC,
four cycles of postoperative platinum-based chemother-
apy are recommended (IA).
• Postoperative chemotherapy is not recommended for
patients with completely resected stage IA NSCLC (IB)
and its use remains controversial in patients with large
IB tumors (C4 cm) (IC).
• In elderly fit patients (B80 years), postoperative plat-
inum-based chemotherapy should be considered as well.
PORT is not recommended for patients with com-
pletely resected stage I–II NSCLC (IA and IIA, respec-
tively) [10].
Stereotactic radiotherapy (SBRT)
SBRT is recommended for patients with node negative
tumors B5 cm who are deemed medically inoperable or
who decline surgery (IIC). Several non-randomized
studies suggested that this technique might be a suit-
able option for operable patients older than 75 years
(IIC).
Targeted agents are not recommended in the postoper-
ative setting. Adjuvant erlotinib did not improve disease-
free survival in patients with EGFR-expressing NSCLC or
in the EGFR mutant subgroup [11]. Several trials are
currently testing the use of targeted therapies in patients
with resected EGFR/ALK positive NSCLC.
Table 2 TNM classification 7a edition (Adapted from Goldstraw et al. [5])
TNM classification
Primary tumor (T)
TX Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not
visualized by imaging or bronchoscopy
T0 No evidence of primary tumor (Tis Carcinoma in situ)
T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more
proximal than the lobar bronchus (for example, not in the main bronchus) [1]
T1a Tumor 2 cm or less in greatest dimension
T1b Tumor more than 2 cm but 3 cm or less in greatest dimension
T2 Tumor more than 3 cm but 7 cm or less or tumor with any of the following features (T2 tumors with these features are classified T2a if
5 cm or less): involves main bronchus, 2 cm or more distal to the carina; invades visceral pleura (PL1 or PL2); associated with
atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a Tumor more than 3 cm but 5 cm or less in greatest dimension
T2b Tumor more than 5 cm but 7 cm or less in greatest dimension
T3 Tumor more than 7 cm or one that directly invades any of the following: parietal pleural (PL3), chest wall (including superior sulcus
tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the
carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor
nodule(s) in the same lobe
T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus,
vertebral body, carina, separate tumor nodule(s) in a different ipsilateral lobe
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct
extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe, tumor with pleural nodules or malignant pleural (or pericardial) effusion
M1b Distant metastasis (in extrathoracic organs)
1022 Clin Transl Oncol (2015) 17:1020–1029
123
Stage III
Stage III NSCLC represents a heterogeneous group of
patients with presentations that range from resectable tu-
mors to unresectable ones. Due to the complexity of most
stage III disease presentations, treatment decision must be
made within an expert multidisciplinary team management
(Fig. 1).
Stage III has been classified into different subgroups:
• In patients with R0 resected NSCLC and an incidental
N2 metastases found on final pathology examination of
the resection specimen, adjuvant chemotherapy should
be given [8] (IA). PORT may be considered (IVC) and
should be administered after adjuvant chemotherapy.
Retrospective analyses from randomized trials suggest
a potential benefit of adjuvant radiotherapy in N2
disease. There is an ongoing European trial (LungART)
evaluating this strategy.
• In patients with N2 documented intra-operatively,
surgery should be followed by adjuvant chemotherapy
(IA) ?/- PORT (IVC).
• In potentially resectable IIIA (N2), several randomized
clinical trials have compared the outcome of primary
surgery versus neoadjuvant therapy followed by
surgery with fairly consistent trend to better survival
for combined treatment. The Cochrane meta-analysis
demonstrated that preoperative therapy is better than
surgery alone for patients with stage III [12]. There are
also several trials that have evaluated the role of
surgery after preoperative therapy compared with a
nonsurgical curative-intent strategy obtaining similar
results. The North American intergroup 0139 study
showed better progression-free survival (PFS) but no
survival except in the unplanned subgroup patients who
underwent lobectomy [13]. The optimal chemotherapy
regimen has not been investigated in randomized
studies, but cisplatin-based chemotherapy is recom-
mended. These patients could be treated with induction
chemotherapy followed by surgery, induction chemora-
diotherapy followed by surgery or concurrent definitive
chemoradiotherapy (IA). Trimodality treatment is
preferably planned in patients in whom a complete
resection by lobectomy is expected.
• In unresectable IIIA (N2) (bulky and multiple medi-
astinal nodal involvement) and IIIB disease, PS 0-1 and
minimal weight loss, concurrent chemoradiotherapy is
the treatment of choice (IA). Several phase III trials and
a meta-analysis based on individual patient data have
showed an overall survival (OS) benefit of 4.5 % at
5 years [14]. For fit patients with inoperable stage III,
2–4 cycles of cisplatin-based chemotherapy is recom-
mended (IA), being etoposide and vinorelbine platinum
combinations the most commonly used. There is no
evidence for induction or consolidation treatment.
• If concurrent chemoradiotherapy is not possible, induc-
tion chemotherapy followed by definitive radiotherapy
is an effective alternative [15] (IA).
• Radiotherapy dose of 60–66 Gy in 30–33 daily frac-
tions of 1.8–2 Gy is recommended for concurrent
chemoradiotherapy. The RTOG 0617 study has demon-
strated that radiation dose of 74 Gy is not superior to
the standard dose [16] (IA).
There is no role for prophylactic cranial irradiation in
stage III [17] (IIA).
There is currently no role for targeted agents in the
treatment of stage III [18] (IA).
Stage IV (Fig. 2)
First line therapy
For stage IV PS 0-1 NSCLC patients, without driver
mutations, a combination of cytotoxic chemotherapy is
recommended, based on tumor histology (IA). Early pal-
liative care is strongly recommended (Fig. 2).
For squamous cell lung cancer (SCC)
• Two drugs platinum based combination must be offered.
Data have shown that platinum combination therapy
increases OS and improves QoL compared to supportive
care [19] (IA). None of the cisplatin or carboplatin
regimens with third generation drugs have shown clear
superiority over others in the treatment of SCC. The
choice of the combination must take into account the
toxicity profile and patient comorbidities (IA).
• Although cisplatin and carboplatin have demonstrated
similar activity, a meta-analysis has reported higher
response rate (RR) and significantly OS increase inFig. 1 Treatment algorithm for Stage III
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patients treated with cisplatin [20]. Carboplatin can be
recommended if any contraindications for cisplatin
exist (IA).
• The non-platinum regimens have reported lower activ-
ity as compared to platinum regimens [21] (IB).
• Four, up to a maximum of six cycles in selected cases,
are recommended [22] (IA).
For non-squamous cell lung cancer (Non-SCC)
• Platinum-doublet combination is also recommended.
Cisplatin/pemetrexed demonstrated more efficacy and
less toxicity compared to cisplatin/gemcitabine [23]
(IA). If any contraindications for cisplatin exist or in
elderly fit patients, the combination pemetrexed/carbo-
platin could be a valuable treatment option [24] (IB).
• Bevacizumab can be added to the first line treatment in
combination with platinum regimens in patients with PS
0-1 and without any specific contraindication for antian-
giogenic therapy (IA). Bevacizumab must continue to be
administered until disease progression or toxicity [25].
• Non-platinum combinations can be considered in some
cases.
• Chemotherapy should be continued for a total of 4–6
cycles in selected cases.
• Maintenance therapy can be considered in those PS 0-1
patients who achieve at least stabilization and have
recovered from toxicities from the previous induction
therapy (IA):
• Pemetrexed and erlotinib can be used as switch
maintenance after four cycles of platinum-base induc-
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Fig. 2 Treatment algorithm for Stage IV
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• Pemetrexed is also indicated in continuation mainte-
nance after four induction cycles of platinum/peme-
trexed [28] (IA).
• Maintenance should be administered until unaccept-
able toxicity or disease progression.
Elderly and PS2:
• Elderly fit patients with PS 0-1 should be treated with
platinum combination chemotherapy according to his-
tology [29] (IA).
• Patients with important comorbidities or PS2 are
suitable for being treated with monotherapy regimen.
• Unfit PS 3-4 patients, should not receive chemotherapy
regardless of age, and supportive care must be recom-
mended. However, patients with EGFR mutations or
ALK rearrangements may also be offered an EGFR or
ALK TKI (IIA).
Solitary metastases Patients with limited disease in chest
and unique metastasis site (mainly solitary brain or adrenal
metastasis) may benefit from an aggressive local therapy
approach (RT, surgery or SBRT) both in the primary and
metastatic site [30] (IIIA).
Second and third line
• Patients clinically or radiologically progressing after
first-line chemotherapy, PS 0-1 should be offered sec-
ond-line treatment (IA).
• Docetaxel, erlotinib, or pemetrexed (only in non-SCC)
have demonstrated improvement in terms of OS and
QoL [31–33] (IA).
• Combination regimens have failed to show any survival
benefit over single agents with more toxicity [34] (IA).
• Erlotinib may be recommended as third-line therapy for
patients with PS of 0-2 who have not received prior
EGFR TKIs (IA).
• Recently, novel therapeutic strategies have demon-
strated significant benefit in OS in the second line
setting, but they have not been approved yet by the
Spanish Agency of Drugs and Sanitary Products
(AEMPS):
• The addition of ramucirumab [35] (monoclonal
antibody against VEGFR-2) to docetaxel, demon-
strated a significant OS benefit compared to
docetaxel alone in previously treated PS 0-1
NSCLC patients.
• Nintedanib [36] (VEGFR 1-3, FGFR 1-3, PDGFR
alpha/beta and RET TKI) added to docetaxel has
demonstrated a significant OS benefit as compared
with docetaxel alone in previously treated stage IV,
PS 0-1 adenocarcinoma.
• Nivolumab, PD-1 monoclonal antibody, improves
the RR and the OS as compared with docetaxel alone
in previously treated SCC NSCLC independently of
the PD-L1 expression [37]. Preliminarily, Nivolu-
mab resulted no survival inferior to docetaxel in the
non-SCC population, but improved overall RR and
OS in patients with PD-L1 overexpression [38].
Targeted therapy for stage IV NSCLC
Significant advances in understanding the molecular biol-
ogy of NSCLC led to the identification of driver alterations
and novel therapeutic targets. The majority of these alter-
ations occur in adenocarcinomas although potential targets
in SCC are also emerging. Drugs targeting the EGFR and
ALK genes, respectively, are currently approved. Testing
for both alterations is recommended upfront in stage IV
non-SCC regardless of clinical characteristics, and in non-
smokers irrespective of histology (IA).
EGFR mutation
The frequency of EGFR mutations in Spanish population is
around 10–16 % of patients. The most commonly found
EGFR mutations are the exon 19 deletions (Del19) and the
exon 21 L858R point mutation (85–90 %).
First-line patients harboring EGFR mutations should be
treated with an EGFR TKI (Gefitinib, Erlotinib, Afatinib)
(IA). Consistent evidence of several phase III trials have
showed superior PFS, RR, toxicity profiles and QoL for
EGFR TKIs compared with platinum-based doublets [39–
41]. These studies did not show statically significant
differences in OS, although a prespecified sub-analysis of
LUX-Lung 3 and 6 trials showed a significant improve-
ment in OS favoring afatinib vs chemotherapy in Del19
patients [42]. The results from direct comparative trials
among different EGFR TKIs are not yet available,
although ongoing randomized trials, comparing first gen-
eration with second and third generation EGFR TKIs are
awaited.
For patients with stage IV NSCLC harboring EGFR
mutations that progressed to first line therapy:
• Rebiopsy is at the time of progression in patients with
EGFR mutations treated with first- or second-genera-
tion EGFR TKIs at front line, and benefits/risks should
be discussed with the patient (IIIC).
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• An EGFR TKI should be recommended if not received
during the first line setting (IA).
• Platinum-based chemotherapy can be recommended
after progression to an EGFR TKI (IIA).
• EGFR T790M gatekeeper mutation is considered to be
the main mechanism of acquired resistance to EGFR
TKIs. Third generation EGFR TKIs such as AZ9291,
Rociletinib, HM61713, EGF 816 or ASP 8273 are
selective for T790M resistance mutation and have
shown significant activity in several phase I and II trials
in patients with acquired resistance to first and second
generation EGFR TKIs. Results from ongoing clinical
trials are awaited to recommend these drugs in the
second line setting.
• Continuing EGFR TKI in combination with platinum-
based chemotherapy beyond progression has failed to
demonstrate a significant benefit and should not be
recommended [43].
ALK gene rearrangement
ALK rearrangements, mainly translocations, occur in
around 4 % of NSCLC.
• For those ALK positive patients, Crizotinib should be
recommended in the first line setting (IA). The phase
III trial PROFILE 1014, compared crizotinib vs plat-
inum-pemetrexed confirming a significant benefit in
terms of PFS, RR and QoL [44].
• If not received during the first line setting, Crizotinib
should be recommended as second-line treatment (IA).
The recommendation is based on the phase III trial
PROFILE 1007, that compared crizotinib vs
chemotherapy (either pemetrexed or docetaxel) in
patients with locally advanced or metastatic ALK
positive NSCLC previously treated. Crizotinib
achieved significant better outcome in terms of PFS,
RR, toxicity profile and QoL [45].
• For those patients progressing on Crizotinib treatment,
Ceritinib, a second generation ALK TKI has received
the approval from the FDA and EMA on the basis of a
phase I single-arm trial obtaining a RR of 56 % and
mPFS of 6.9 months [46] (IIB).
• Chemotherapy may still be appropriate in the absence
of phase III data comparing ceritinib with chemother-
apy. The chemotherapy regimens are the same as were
recommended as first-line using platinum-based com-
binations (IA).
• Other ALK inhibitors under investigation include alec-
tinib, brigatinib and lorlatinib have been reported to
have high activity in ALK positive patients including
patients with brain metastases. Results from ongoing
clinical trials evaluating new ALK TKIs are awaited.
Other targetable genetic alterations
The prevalence of other molecular alterations with poten-
tially actionable drugs is low (\2 %). None of these tar-
geted drugs has regulatory approval. Routine testing for
these biomarkers is not currently recommended (IIIC).
Early clinical trials have shown the activity of targeting
drugs as crizotinib (ROS1 fusion and MET amplification),
vemurafenib and dabrafenib or dabrafenib plus trametinib
(BRAF mutations), anti-HER2 monoclonal antibodies or
HER2 TKIs (HER2 mutations) and other potential drugs
targeting RET fusion, PI3 K mutations and others. How-
ever, no active agent has been clinically proven yet in
KRAS mutations. Available evidence for the use of these
agents is limited based in early clinical trials (Table 3).
Follow-up
Follow-up frequency in patients with NSCLC is a contro-
versial issue.
After curative-intent
• In patients who have had surgery, follow-up visit
including history, physical examination and spiral chest
CT is recommended every 6–12 months for the first
2 years and annually thereafter (IIIB).
• For patients who have undergone curative-intent ther-
apy, routine surveillance with blood test, PET imaging
or another radiological assessment is not recommended
(IID).
• For patients treated with SBRT, CT scans every
6 months for 3 years are recommended if patients are
suitable for salvage treatment (IIIB). The use of FDG-
PET (and biopsy if positive) is recommended when
recurrence after SBRT is suspected based on chest CT
(IIIB).
In advanced disease patients:
• Treatment response is recommended to be evaluated 9
or 12 weeks after treatment begins, using the same
radiographic method used at baseline. Depending on
individual clinical judgement, a repeat scan might be
performed after 6 weeks.
• For patients eligible for active cancer therapy in
successive lines of treatment, it is advisable to undergo
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Table 3 Summary of recommendations
Recommendations
Diagnosis
Pathological diagnosis should be made according to the WHO classification and
IASLC classification of adenocarcinoma
For therapeutic implications, specific subtyping of NSCLC is strongly
recommended whenever possible
Limited panel of immunohistochemistry markers is strongly recommended in
order to preserve as much tissue as possible for further molecular assessments
Testing for EGFR mutations and ALK translocations are recommended in all
patients with advanced-stage non-SCC, regardless of clinical characteristics and
in never smokers irrespective of histology
Stage I–II
Patients medically fit for surgery Lobectomy plus systematic lymph node sampling or dissection
Patients medically inoperable, node negative,
tumors\ 5 cm
SBRT
Post-operative radiotherapy (PORT) Not indicated in completely resected stage I-II
Adjuvant chemotherapy (four cycles of adjuvant cisplatin-
based chemotherapy
Not indicated in stage IA
May be considered in selected patients with stage IB
Recommended in stage II
Targeted agents Not recommended
Stage III
Postoperative IIIA (N2) Adjuvant platinum-based chemotherapy ± PORT
Preoperative resectable IIIA (N2) Definitive concurrent chemo/radiotherapy
Induction chemotherapy or induction chemoradiotherapy followed by surgery
evaluation
Unresectable IIIA (N2), IIIB PS 0-1: definitive concurrent chemoradiotherapy
PS 2: sequential chemoradiotherapy
Stage IV without driver mutations
First line setting
For PS 0-1, platinum-based doublets are recommended
based on tumor histology
Non-SCC Platinum-based doublet
Cisplatin/pemetrexed doublet has demonstrated more efficacy and less toxicity
compared to cisplatin/gemcitabine
Bevacizumab added to a platinum doublet if there are no contraindications.
Bevacizumab must continue to be administered until disease progression or
toxicity
SCC Platinum-based doublet
Elderly Elderly fit patients with PS 0-1 should be treated with platinum combination
chemotherapy according to histology
PS 0-2 Patients with important comorbidities or PS2 are suitable for being treated with
monotherapy regimen
Maintenance For PS 0-1, non-SCC patients with stable disease or response after four cycles
Pemetrexed or erlotinib can be used as switch maintenance
Pemetrexed is also indicated in continuation maintenance after four induction
cycles of platinum/pemetrexed
Second line setting and beyond For PS 0-2, docetaxel, erlotinib, or pemetrexed (only in non-SCC)
Erlotinib may be recommended as third-line therapy for patients with PS of 0-2
who have not received prior EGFR TKIs
Stage IV EGFR Mut NSCLC
First-line stage IV EGFR Mut NSCLC Gefitinib, erlotinib, afatinib
EGFR Mut patients who have not received and EGFR TKI
as first line
Gefitinib, erlotinib, afatinib
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clinical and/or radiological evaluation 6 weeks after
finishing treatment and then every 6–12 weeks to
enable second-line therapy to commence promptly
(IIIB).
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